Regaining compliance with Nasdaq listing requirements is a significant positive development for Adial Pharmaceuticals. It removes the immediate threat of delisting, which can be a major concern for investors and can negatively impact stock price. With this risk mitigated, investor sentiment towards ADIL may improve, leading to a potential increase in the stock price in the short term. However, the long-term impact will depend on the company's ongoing performance and market conditions.